USP22 and non-small cell lung carcinoma: Statistical analysis showed that the intensities of USP22 immunostainings were positively associated with cancer recurrence (P = 0.044) and a trend toward advanced stage (P = 0.088) (Table 1) in these NSCLC tissues.